DK2962113T3 - Systemer og fremgangsmåder med anti-p40-antistoffer - Google Patents

Systemer og fremgangsmåder med anti-p40-antistoffer

Info

Publication number
DK2962113T3
DK2962113T3 DK14756627.7T DK14756627T DK2962113T3 DK 2962113 T3 DK2962113 T3 DK 2962113T3 DK 14756627 T DK14756627 T DK 14756627T DK 2962113 T3 DK2962113 T3 DK 2962113T3
Authority
DK
Denmark
Prior art keywords
antibodies
systems
methods
Prior art date
Application number
DK14756627.7T
Other languages
Danish (da)
English (en)
Inventor
David Tacha
Weimin Qi
Original Assignee
Biocare Medical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocare Medical Llc filed Critical Biocare Medical Llc
Application granted granted Critical
Publication of DK2962113T3 publication Critical patent/DK2962113T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK14756627.7T 2013-02-28 2014-02-28 Systemer og fremgangsmåder med anti-p40-antistoffer DK2962113T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361770956P 2013-02-28 2013-02-28
PCT/US2014/019705 WO2014134587A1 (en) 2013-02-28 2014-02-28 Anti-p40 antibodies systems and methods

Publications (1)

Publication Number Publication Date
DK2962113T3 true DK2962113T3 (da) 2019-07-01

Family

ID=51428881

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14756627.7T DK2962113T3 (da) 2013-02-28 2014-02-28 Systemer og fremgangsmåder med anti-p40-antistoffer

Country Status (6)

Country Link
US (2) US9428576B2 (https=)
EP (1) EP2962113B1 (https=)
JP (1) JP6445467B2 (https=)
DK (1) DK2962113T3 (https=)
ES (1) ES2720483T3 (https=)
WO (1) WO2014134587A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852592B2 (en) 2011-05-10 2014-10-07 Biocare Medical, Llc Systems and methods for anti-PAX8 antibodies
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
EP2900265B1 (en) 2012-09-27 2018-05-30 Biocare Medical, LLC Anti-uroplakin ii antibodies systems and methods
US10429390B2 (en) 2012-12-18 2019-10-01 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
DK2962113T3 (da) 2013-02-28 2019-07-01 Biocare Medical Llc Systemer og fremgangsmåder med anti-p40-antistoffer
BR112015023120A2 (pt) 2013-03-15 2017-11-21 Genentech Inc método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
US9816997B2 (en) 2013-10-03 2017-11-14 Biocare Medical, Llc Anti-SOX10 antibody systems and methods
RU2715038C2 (ru) 2014-07-11 2020-02-21 Дженентек, Инк. Антитела анти-pd-l1 и способы их диагностического применения
TWI782434B (zh) 2015-08-28 2022-11-01 德商英麥提克生物技術股份有限公司 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
CN108467433B (zh) * 2018-05-30 2021-05-07 福州迈新生物技术开发有限公司 抗Napsin A蛋白的单克隆抗体及其细胞株、制备方法和应用
WO2020243733A1 (en) * 2019-05-30 2020-12-03 Sakura Finetek Usa, Inc. Detection of antigens in a biological specimen using antibody reagents
US11976282B2 (en) 2020-06-23 2024-05-07 Qatar University GATA3 inhibitors for the promotion of subcutaneous fat deposition
US20230331865A1 (en) * 2020-08-26 2023-10-19 Agilent Technologies, Inc. Antibodies for use in immunohistochemistry (ihc) protocols to diagnose cancer
WO2026058045A1 (en) 2024-09-12 2026-03-19 Takeda Pharmaceutical Company Limited Alpha4beta7 inhibitor and il-23 inhibitor combination therapy

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4145406A (en) 1977-04-11 1979-03-20 Miles Laboratories, Inc. Specific binding - adsorbent assay method and test means
US4254082A (en) 1978-06-12 1981-03-03 Miles Laboratories, Inc. Specific binding-adsorbent assay test means
CA1247538A (en) 1982-05-21 1988-12-28 Mark C. Glassy Human-human hybridomas for solid tumors
US4687732A (en) 1983-06-10 1987-08-18 Yale University Visualization polymers and their application to diagnostic medicine
US4690890A (en) 1984-04-04 1987-09-01 Cetus Corporation Process for simultaneously detecting multiple antigens using dual sandwich immunometric assay
JPS60248618A (ja) 1984-05-24 1985-12-09 Nippon Zoki Pharmaceut Co Ltd ジペプチドを含有する潰瘍治療剤
US4792521A (en) 1985-08-15 1988-12-20 Immunomedics, Inc. Non-enzymatic immunohistochemical staining system and reagents
US4863875A (en) 1985-08-26 1989-09-05 Gia Research Company, L.P. Dye labelled antibodies as reagents for use in immunoassay systems
GB8607101D0 (en) 1986-03-21 1986-04-30 Serono Diagnostics Ltd Immunoassay
US5089423A (en) 1987-05-06 1992-02-18 Cyberfluor Inc. Immunoassay methods and reagents and methods for producing the latter
US5620845A (en) 1988-06-06 1997-04-15 Ampcor, Inc. Immunoassay diagnostic kit
US5252487A (en) 1989-05-19 1993-10-12 Cell Analysis Systems, Inc. Method and apparatus for determining the amount of oncogene protein product in a cell sample
US6008057A (en) 1989-08-25 1999-12-28 Roche Diagnostics Corporation Immunoassay system
US5719063A (en) 1989-08-25 1998-02-17 Boehringer Mannheim Corporation Multiplex immunoassay system
EP0513332A4 (en) 1990-11-14 1993-03-17 Cargill, Incorporated Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5280108A (en) * 1991-09-27 1994-01-18 United States Of America Antibodies to p40
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5482698A (en) 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
US5487975A (en) 1993-11-15 1996-01-30 Ventana Medical Systems, Inc. Biotin/avidin formulation
EP0742830B1 (en) 1994-02-01 2001-07-18 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Fusion proteins that include antibody and nonantibody portions
US5869274A (en) 1995-08-09 1999-02-09 Zymed Laboratories, Inc. Immuno-histochemical method that reduces background staining
US5891658A (en) 1996-06-27 1999-04-06 FCI--FiberChem, Inc. Single-step, solid-state competitive immunoassay
EP1283268A3 (en) 1996-08-23 2004-01-02 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor D (VEGF-D)
US7196164B2 (en) 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
AU9498098A (en) 1997-09-22 1999-04-12 Chiron Corporation Buffers for stabilizing antigens
US7294459B1 (en) 1997-10-15 2007-11-13 President And Fellows Of Harvard College Cell regulatory genes, encoded products, and uses related thereto
US6476206B1 (en) * 1998-03-27 2002-11-05 The Johns Hopkins University p40 protein acts as an oncogene
JP3524401B2 (ja) 1998-09-16 2004-05-10 株式会社ニチレイ 酵素抗体複合体およびその製造方法
EP1178838B1 (en) 1999-05-14 2004-09-29 The Regents of the University of California Macromolecular carrier based on dextran for drug and diagnostic agent delivery
US6723506B2 (en) 2000-01-20 2004-04-20 Brigham And Women's Hospital Method of identifying PAX8-PPAR gamma-nucleic acid molecules
US20030017491A1 (en) 2000-09-14 2003-01-23 Zuo-Rong Shi Chromogenic in situ hybridization methods, kits, and compositions
DE10063179A1 (de) 2000-12-18 2002-06-20 Bayer Ag Verfahren zur spezifischen Detektion von Tumorzellen und ihren Vorstufen in Gebärmutterhalsabstrichen durch simultane Messung von mindestens zwei verschiedenen molekularen Markern
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20020173053A1 (en) 2001-04-27 2002-11-21 Bassam Damaj Multiple simultaneous antigen detection by immunohistochemistry
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
US6580056B1 (en) 2001-09-21 2003-06-17 Biocare Medical Biological specimen heating device and quality control method for immunohistochemistry heat retrieval procedures
EP1480520A4 (en) 2002-02-12 2006-02-15 Raven Biotechnologies Inc EPITHELIAL CELLS FROM THE HUMAN FOLDS BUBBLE
NZ535425A (en) 2002-03-13 2008-05-30 Biogen Idec Inc Anti-alphavbeta6 antibodies
US7850912B2 (en) * 2003-05-14 2010-12-14 Dako Denmark A/S Method and apparatus for automated pre-treatment and processing of biological samples
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
JP2007501021A (ja) 2003-05-30 2007-01-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 遺伝子操作された定常領域を含む、抗体および融合タンパク質
JP4949038B2 (ja) 2003-12-01 2012-06-06 ダコ デンマーク アクティーゼルスカブ 免疫組織化学的検出のための方法および組成物
WO2005076005A2 (en) 2004-01-30 2005-08-18 Medizinische Universität Wien A method for classifying a tumor cell sample based upon differential expression of at least two genes
US20050186642A1 (en) 2004-02-24 2005-08-25 Biocare Medical, Inc. Immunoassay reagents and methods of use thereof
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
EP1904531B1 (en) 2005-07-08 2010-10-06 Pfizer Limited Madcam antibodies
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
US8691224B2 (en) * 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
CA2652703C (en) * 2006-06-07 2018-08-28 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
EP2050466B1 (en) 2006-08-14 2015-10-28 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
WO2008073300A2 (en) 2006-12-08 2008-06-19 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angptl3
US20080267988A1 (en) 2007-04-11 2008-10-30 Enteron Limited Partnership Myelin specific IgE unencumbered by corresponding blocking antibodies as a causative factor in multiple sclerosis
JP5117765B2 (ja) 2007-05-28 2013-01-16 国立大学法人 東京大学 抗ｒｏｂｏ１抗体を含むｐｅｔ用腫瘍診断剤
MY151191A (en) 2007-09-26 2014-04-30 Genentech Inc Novel antibodies
WO2010022736A2 (en) 2008-08-29 2010-03-04 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
US7846762B2 (en) 2008-09-22 2010-12-07 Applied Materials, Inc. Integrated emitter formation and passivation
US9040667B2 (en) 2009-05-01 2015-05-26 Dako Denmark A/S Antibody cocktail
NZ596274A (en) * 2009-05-12 2013-11-29 Pfizer Blocking anti-dkk-1 antibodies and their uses
WO2011047019A1 (en) 2009-10-13 2011-04-21 Yale University An objective, quantitative method to predict histological subtype in non-small cell lung cancer
US20120321557A1 (en) 2010-02-26 2012-12-20 Forerunner Pharma Research Co., Ltd. Anti-icam3 antibody and use thereof
EP2402370A1 (en) * 2010-06-29 2012-01-04 Pierre Fabre Médicament Novel antibody for the diagnosis and/or prognosis of cancer
AU2011295715B9 (en) 2010-09-03 2017-02-23 Abbvie Stemcentrx Llc Novel modulators and methods of use
WO2012048154A1 (en) 2010-10-06 2012-04-12 Biocare Medical, Llc Methods and systems for efficient processing of biological samples
US8852592B2 (en) 2011-05-10 2014-10-07 Biocare Medical, Llc Systems and methods for anti-PAX8 antibodies
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
EP2900265B1 (en) 2012-09-27 2018-05-30 Biocare Medical, LLC Anti-uroplakin ii antibodies systems and methods
US10429390B2 (en) * 2012-12-18 2019-10-01 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
DK2962113T3 (da) 2013-02-28 2019-07-01 Biocare Medical Llc Systemer og fremgangsmåder med anti-p40-antistoffer
US9816997B2 (en) 2013-10-03 2017-11-14 Biocare Medical, Llc Anti-SOX10 antibody systems and methods

Also Published As

Publication number Publication date
WO2014134587A1 (en) 2014-09-04
JP6445467B2 (ja) 2019-01-09
US9428576B2 (en) 2016-08-30
JP2016516008A (ja) 2016-06-02
ES2720483T3 (es) 2019-07-22
EP2962113B1 (en) 2019-04-03
EP2962113A1 (en) 2016-01-06
US20160333085A1 (en) 2016-11-17
EP2962113A4 (en) 2016-11-09
US9708395B2 (en) 2017-07-18
US20160009795A1 (en) 2016-01-14

Similar Documents

Publication Publication Date Title
IL271562B (en) Vaporization device systems and methods
IL261743B (en) and their uses 33–il antibodies against
IL261547B (en) Antibodies against pesidine and their uses
DK2962113T3 (da) Systemer og fremgangsmåder med anti-p40-antistoffer
IL245040A0 (en) Antibodies against pdgfr-beta and their uses
IL243974B (en) Antibodies against –prlr and uses
ZA201508896B (en) Anti-c10orf54 antibodies and uses thereof
DK3089994T3 (da) Fabs-in-tandem-immunglobulin og anvendelser deraf
DK3079719T3 (da) ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf
PL3804863T5 (pl) Sposób aplikacji i system aplikacji
SG11201509618QA (en) Anti-b7-h5 antibodies and their uses
PL3406633T3 (pl) Przeciwciała wieloswoiste, aktywowalne przeciwciała wieloswoiste i metody ich stosowania
IL243425A0 (en) Formulations and methods based on antibodies
SG11201509116VA (en) Anti-tweakr antibodies and uses thereof
DK3052522T3 (da) Anti-sox 10 antistofsystemer og -fremgangsmåder
DK2951208T3 (da) Anti-cd83 antistoffer og anvendelse deraf
BR112016000304A2 (pt) Sistema e método
TH1501000260A (th) วิธีการและระบบการพิสูจน์ตัวจริง